11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial (Q38953228)
Jump to navigation
Jump to search
scientific article published on 16 February 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial |
scientific article published on 16 February 2017 |
Statements
1 reference
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial (English)
1 reference
1 reference
Jose Baselga
1 reference
Luca Gianni
1 reference
Michael Untch
1 reference
Mitch Dowsett
1 reference
Aron Goldhirsch
1 reference
Marion Procter
1 reference
Herceptin Adjuvant (HERA) Trial Study Team
1 reference
Christian Jackisch
1 reference
David Cameron
1 reference
Martine J Piccart-Gebhart
1 reference
Richard D Gelber
1 reference
Gilberto Castro
1 reference
Ian Smith
1 reference
Nedal Al-Sakaff
1 reference
Sabine Lauer
1 reference
Eleanor McFadden
1 reference
Brian Leyland-Jones
1 reference
Richard Bell
1 reference
17 February 2017
1 reference
1 reference
389
1 reference
10075
1 reference
1195-1205
1 reference
Identifiers
1 reference
1 reference